Growth Hormone Regulated Gene Expression: A Brief Note

Growth Hormone (GH) exerts a various array of physiological actions that has major roles in growth and metabolism. the first somatomedin hypothesis of Salmon and Daugh each day proposed that a serum factor controlled by GH, or somatomedin, was directly liable for stimulating sulfate incorporation by cartilage, and a number of other lines of investigation have since identified Insulin-like growth factor 1 (IGF-1) because the principal somatomedin liable for this effect. In support of the somatomedin hypothesis, many of the characteristic phenotypic features of GH deficiency are indeed recapitulated with mutations of the gene encoding IGF-1 in both rodents and humans although there are now a way better recognition of the role of local tissue-derived IGF-1 production, instead of strictly endocrine-acting serum IGF-1, on mediating many of the consequences of GH.

GH treatment restores growth velocity in children with GH deficiency, whereas replacement therapy in adults improves body composition, exercise capacity, skeletal integrity, and quality of life measures. GH has been alleged to have an antiaging effect, but diminished signaling of the GH-IGF-1 axis has been related to longevity across many species, intimating deleterious effects from this pathway. Indeed this phenomenon extends even to humans and has been attributed to reduced risks in 2 major contributors to mortality, cancer and diabetes. It follows that better understanding of the molecular mechanisms underlying GH action has important implications to human health and disease. Since the somatomedin hypothesis of somatotropin (GH) action on growth was first formulated in 1957, the key roles of both GH and insulin-like growth factor-I (IGF-I) in human growth are extended to incorporate important effects on tissue maintenance and repair. Newer observations have revealed that this pathway features a negative side, because it has been implicated as a possible contributor to the event of several human cancers and has been linked to diminished lifespan in experimental animals. From the past studies, much has been learned about the physiology of the GH insulin-like growth factor-I (IGF-I) growth axis. The central roles of this pathway in normal pre- and postnatal growth in mammals are extended to incorporate actions on tissue maintenance, regeneration, and repair within the adult. Alongside a clearer definition of positive actions of GH and IGF I, an appreciation of their potentially harmful effects has been established. The negative roles of excessive GH on glucose metabolism and on cardiovascular function in acromegaly are long known, as have the pathogenic effects of both GH and IGF-I in proliferative diabetic retinopathy. GH and IGF-I actions even have been linked in experimental animals to accelerated aging, and IGF-I has been found in epidemiological studies in humans and in experimental models in animals to contribute too many sorts of cancer. Taken together, these studies emphasize the importance of understanding the essential biochemistry and biology of the GH-IGF-I pathway so as to modulate its effects on human health and disease.

Endocrinology and Metabolism: Open Access is a peer reviewed journal which focuses on the publication of current research and developments on the endocrine glands and its secretions with their coordination with metabolism and reproduction.

Endocrinology and Metabolism: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Endocrinology and Metabolism: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Journal is now accepting manuscripts for volume 5 for year 2021. We publish minimum of 5 and maximum of 20 articles per issue every month. Submissions to our journal are given high priority during the process.

Submit your manuscript at:

https://www.imedpub.com/submissions/endocrinology-metabolism-open-access.html 

You may also send the manuscript as an attachment to mail endometabol@emedscholar.com

Media Contact
Eliza Grace
Associate Managing Editor
Endocrinology and Metabolism: Open Access
E-Mail: endometabol@emedscholar.com